CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
- Conditions
- Ovarian CancerPeritoneal CancerEpithelial Ovarian CancerOther Solid TumorMetastatic Castration-Resistant Prostate CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 34
- Registration Number
- NCT04676334
- Locations
- 🇮🇱
Carmel Medical Center, Haifa, Israel
🇮🇹Istituto per la Ricerca e la Cura del Cancro Istituto di Candiolo, Candiolo, Torino, Italy
🇨🇦Institut De Recherche De L'Hospital D'Ottawa, Ottawa, Ontario, Canada
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 8
- Registration Number
- NCT04179396
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Urology Associates, P.C., Nashville, Tennessee, United States
🇺🇸Piedmont Cancer Institute, P.C., Atlanta, Georgia, United States
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 83
- Registration Number
- NCT04171700
- Locations
- 🇺🇸
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸New York Cancer and Blood Specialists, Port Jefferson Station, New York, United States
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
- Conditions
- Multiple Myeloma
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 248
- Registration Number
- NCT04150289
- Locations
- 🇺🇸
American Health Network Indiana, Indianapolis, Indiana, United States
🇺🇸Oncology Specialists of Charlotte, Charlotte, North Carolina, United States
🇺🇸Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
- Conditions
- Triple-negative Breast CancerOvarian CancerUrothelial CarcinomaSolid Tumor
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT03992131
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT03954366
- Locations
- 🇵🇱
Zdrowie Kobiety Centrum Leczniczo-Rehabilitacyjne i Medycyny Pracy ATTIS Sp. z o.o., Zakład Onkologii Kobiecej, Warszawa, Poland
🇸🇰Summit Clinical Research s.r.o., Bratislava, Slovakia
ðŸ‡ðŸ‡ºPRA Magyarország Fázis I-es Klinikai Farmakológiai Vizsgálóhely FMC DialÃzis Központ, II. em., Budapest, Hungary
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
- Conditions
- Epithelial Ovarian CancerPrimary Peritoneal CarcinomaHigh Grade Serous CarcinomaEndometrioid AdenocarcinomaFallopian Tube Cancer
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 1
- Registration Number
- NCT03824704
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Community Cancer Institute, Clovis, California, United States
🇺🇸Memorial Health University Medical Center, Savannah, Georgia, United States
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 16
- Registration Number
- NCT03521037
- Locations
- 🇵🇱
Zachodniopomorskie Centrum Onkologii w Szczecinie, Szczecin, Poland
🇬🇧Northern Centre for Cancer Care, Newcastle Upon Tyne, United Kingdom
🇵🇱BioVirtus Centrum Medyczne, Warszawa, Poland
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
- Conditions
- Partial ResponseNewly DiagnosedComplete ResponsePrimary PeritonealEpithelial Ovarian CancerFallopian Tube CancerFIGO Stage III-IV
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 1097
- Registration Number
- NCT03522246
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
🇺🇸Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 29
- Registration Number
- NCT03499444
- Locations
- 🇯🇵
Department of Gynecologic Oncology, Saitama Medical Univeristy international Medical Center, Hidaka, Saitama, Japan
🇯🇵Department of Breast and Medical Oncology, National Cancer Center Hospital, Tsukiji, Tokyo, Japan
🇯🇵Division of Medical Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan